Tradestie Institutional Equity Comparison Engine
LYRA vs BAX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BAX Overall Edge
BAX Captures Institutional Edge (4โ0 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Baxter International Inc. (BAX) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, LYRA trades at N/M Forward P/E with -25032.0% operating margin (-87.2% YoY revenue) versus BAX at 12.5x Forward P/E and 7.6% operating margin (+5.0% YoY). In options structure, LYRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against BAX sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
BAX
LYRA N/M vs BAX 12.5x Fwd P/E
Growth & Margin Winner
BAX
Op Margin -25032.0% vs 7.6% ยท YoY -87.2% vs +5.0%
Momentum & Technical Winner
BAX
1Y -94.3% vs +39.9% ยท 52W Pos 1% vs 71%
Options & Structure Winner
BAX
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (5th %ile IV)
LYRA
NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap
$2.3M
1M Return
-62.5%
1Y Return
-94.34%
Forward P/E
N/M
Unified AI Score
52.2 / 100
HOLD
Tech 60.0
Fund 56.0
Flow 50.0
Mom 59.0
BAX
NYSE
Baxter International Inc.
Surgical & Medical Instruments & Apparatus
$25.83
+1.14% 1D
Market Cap
$13.4B
1M Return
+3.36%
1Y Return
+39.85%
Forward P/E
12.5x
Unified AI Score
46.5 / 100
HOLD
Tech 47.0
Fund 56.0
Flow 71.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
LYRA -94.34%
BAX +39.85%
Spread: +79.61 pp (BAX Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | LYRA Revenue | BAX Revenue | LYRA Op. Margin | BAX Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $11.1B | N/A | 14.3% | BAX |
| FY2019 | N/A | $11.4B | N/A | 15.6% | BAX |
| FY2020 | N/A | $11.7B | N/A | 13.8% | BAX |
| FY2021 | $0M | $12.2B | -15303.5% | 11.1% | BAX |
| FY2022 | $0M | $10.1B | -4131.0% | -28.3% | BAX |
| FY2023 | $0M | $10.4B | -4308.1% | 6.8% | BAX |
| FY2024 | $0M | $10.6B | -6280.8% | 0.1% | BAX |
| FY2025 | $0M | $11.2B | -7794.5% | -2.7% | BAX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | LYRA | BAX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.3M | $13.4B | Larger Scale | BAX |
| Trailing P/E Ratio Valuation | N/M | 12.2x | Lower Multiple | BAX |
| Forward P/E Ratio Valuation | N/M | 12.5x | Lower Multiple | BAX |
| Revenue Growth (YoY) Growth | -87.2% | +5.0% | Higher Growth | BAX |
| Operating Margin (TTM) Profitability | -25032.0% | 7.6% | Higher Margin | BAX |
| Net Profit Margin Profitability | 0.0% | -6.2% | Higher Margin | LYRA |
| Return on Equity (ROE) Capital Efficiency | -404.5% | -9.0% | Higher ROE | BAX |
| 52-Week Range Position Momentum | 1% ($0โ$38) | 71% ($16โ$30) | Stronger Trend | BAX |
| Beta / 30D Volatility Risk Regime | 0.33ฮฒ ยท 248% Vol | 0.95ฮฒ ยท 47% Vol | Lower Realized Risk | BAX |
| Unified Institutional Score Composite Signal | 52.2 / 100 (HOLD) | 46.5 / 100 (HOLD) | Higher Composite | LYRA |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full LYRA vs BAX Buy Guide
LYRA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
BAX
CONSOLIDATION
74d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
5th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither LYRA nor BAX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.